<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04656067</url>
  </required_header>
  <id_info>
    <org_study_id>DR,ABDELAZIM SOBHI</org_study_id>
    <nct_id>NCT04656067</nct_id>
  </id_info>
  <brief_title>Comparative Study Between Oxytocin Versus Tranexamic Acid and Ethamsylate</brief_title>
  <official_title>Comparative Study Between Oxytocin Versus Tranexamic Acid and Ethamsylate to Reduce Blood Loss Intraoperative and Post Operative During Elective Cesarean Section</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Egymedicalpedia</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ALAZHAR UNIVERSITY</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Egymedicalpedia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparative Study Between Oxytocin Versus Tranexamic Acid and Ethamsylate, Pre-operative&#xD;
      Administration.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Caesarean Delivery commonly referred to as caesarean section and occasionally caesarean birth&#xD;
      is defined as the delivery of a foetus(es) through surgical incisions made through the&#xD;
      anterior abdominal wall (technically referred to as laparotomy) and the anterior uterine wall&#xD;
      (technically denoted to as hysterotomy).&#xD;
&#xD;
      Obstetric Hemorrhage (Intra operative OR post operative bleeding)is still the major cause of&#xD;
      maternal morbidity and mortality worldwide contributing to nearly 25% of direct maternal&#xD;
      deaths. And accounts for 50% of maternal mortality in low-income countries.&#xD;
&#xD;
      So many Strategies reducing the intraoperative blood loss or post operative blood loss could&#xD;
      be helpful in decreasing the risks of blood transfusion and the postoperative maternal&#xD;
      morbidity.&#xD;
&#xD;
      So these Medications are such as Oxytocin, Carbetocin, Misoprostol, Prostaglandin F2 alpha,&#xD;
      methylergonovine, Tranexamic acid and Etamsylate . have been tried before to control bleeding&#xD;
      during and after Cesarean Section.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2020</start_date>
  <completion_date type="Actual">November 10, 2020</completion_date>
  <primary_completion_date type="Actual">October 1, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intraoperative and Post operative bleeding(defined as blood loss â‰¥500 cc)</measure>
    <time_frame>First 2 hours after C-Section</time_frame>
    <description>Outcome of the study will be measured in terms of assessment of Hemoglobin level and Hematocrit level pre and post operatively.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sever PPH as bleeding is &gt;1000 cc</measure>
    <time_frame>first 24 hours after C-Section</time_frame>
    <description>Outcome of the study will be measured in terms of assessment of Hemoglobin level and Hematocrit level post operatively.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">230</enrollment>
  <condition>Blood Loss, Surgical</condition>
  <condition>Blood Loss, Postoperative</condition>
  <arm_group>
    <arm_group_label>Oxytocin(only)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oxytocin is given IV infusion 5-10 minutes before the start of skin incision in the Elective Cesarean Section</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tranexamic acid and Ethamsylate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tranexamic acid and Ethamsylate are given IV slowly 5-10 minutes before the start of skin incision in the Elective Cesarean Section</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin ,Tranexamic acid and Ethamsylate</intervention_name>
    <description>Is to compare blood loss during elective cesarean section intraoperative and postoperative in cases receiving Oxytocin versus Tranexamic acid and Ethamsylate</description>
    <arm_group_label>Oxytocin(only)</arm_group_label>
    <arm_group_label>Tranexamic acid and Ethamsylate</arm_group_label>
    <other_name>Syntocinon , Kapron</other_name>
    <other_name>Dicynon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Pregnant females admitted for elective Cesarean Section.&#xD;
&#xD;
          2. Gestational age (38 to 41 weeks).&#xD;
&#xD;
          3. Age of the participants: 20 to 40 years.&#xD;
&#xD;
          4. Body Mass Index (18.5 - 29.9).&#xD;
&#xD;
          5. Singleton living fetus.&#xD;
&#xD;
          6. No medical disorders.&#xD;
&#xD;
          7. Informed written consent from the candidates.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. - Medical and surgical disorders as thyroid dysfunction, which was excluded by routine&#xD;
             thyroid function test (free T3, free T4, and thyroid-stimulating hormone(TSH), all of&#xD;
             them should be within normal limits).&#xD;
&#xD;
          2. -Bleeding tendency, was excluded by platelet count, coagulation time, bleeding time,&#xD;
             prothrombin time, partial thromboplastin time, and thrombin time (all should be within&#xD;
             normal).&#xD;
&#xD;
          3. -Acute and chronic liver or kidney diseases; blood disorders, such as anemia.&#xD;
&#xD;
          4. -Allergy to Tranexamic acid or any drug used.&#xD;
&#xD;
          5. -Risk factors for PPH, such as polyhydramnios, fetal macrosomia, antepartum&#xD;
             hemorrhage.&#xD;
&#xD;
          6. - Abnormal placentae such as placenta previa and placental abruption.&#xD;
&#xD;
          7. -Pregnancy complications such as severe pre-eclampsia, Gestational HTN, Gestational&#xD;
             DM, and multi Fetal pregnancies, those requiring blood transfusion.&#xD;
&#xD;
          8. - Patients who refused spinal anesthesia.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr.,AbdelSattar M Farhan, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Al-Azhar University, Faculty of medicine for boys</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr.,ElSayed A. ElDesouky, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Al-Azhar University, Faculty of medicine for boys</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sayed Galal Hospital and Shoubra General Hospital</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 26, 2020</study_first_submitted>
  <study_first_submitted_qc>November 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2020</study_first_posted>
  <last_update_submitted>February 10, 2021</last_update_submitted>
  <last_update_submitted_qc>February 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Egymedicalpedia</investigator_affiliation>
    <investigator_full_name>DR.ABDELAZIM</investigator_full_name>
    <investigator_title>Assistant specialist</investigator_title>
  </responsible_party>
  <keyword>blood loss</keyword>
  <keyword>Cesarean Section</keyword>
  <keyword>Oxytocin</keyword>
  <keyword>Tranexamic acid(Kapron)</keyword>
  <keyword>Etamsylate(Dicynon).</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Blood Loss, Surgical</mesh_term>
    <mesh_term>Postoperative Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
    <mesh_term>Ethamsylate</mesh_term>
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Is to compare blood loss during elective cesarean section intraoperative and postoperative in cases receiving Oxytocin versus Tranexamic acid and Etamsylate .</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

